Investor Relations

Cassava Sciences, Inc. is a biopharmaceutical company that develops novel drugs.

Presentations

Financial Information

Press Releases

Cassava Sciences Announces Full-year 2020 Financial Results and Business Highlights

Mar 23, 2021

AUSTIN, Texas , March 23, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the year ended December 31, 2020 and provided business updates.

Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam

Mar 09, 2021

AUSTIN, Texas , March 09, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, today announced it has entered into a drug supply agreement with Evonik Industries AG for simufilam.

View all